TABLE 1.
Demographic and treatment characteristics of all patients seen for routine pediatric long‐term follow‐up visits between May 5 and Sept 10, 2020
| Characteristic | All patients (n = 321) | (%) | Patients with positive SARS‐CoV‐2 IgG (n = 20) | (%) |
|---|---|---|---|---|
| Age at diagnosis, years | ||||
| Median (range) | 3.7 (0‐18) | 4.1 (0‐15.8) | ||
| Sex, No. (%) | ||||
| Male | 154 | (48.0) | 9 | (45) |
| Race/Ethnicity, No. (%) | ||||
| White, Non‐Hispanic | 224 | (69.8) | 11 | (55) |
| White, Hispanic | 17 | (5.3) | 0 | (0) |
| Black, Non‐Hispanic | 16 | (5.0) | 3 | (15) |
| Black, Hispanic | 8 | (2.5) | 1 | (5) |
| Asian | 39 | (12.1) | 3 | (15) |
| Other/unknown | 17 | (5.3) | 2 | (10) |
| Diagnosis, No. (%) | ||||
| Leukemia/lymphoma | 91 | (28.4) | 5 | (25) |
| Neuroblastoma | 61 | (19.0) | 1 | (5) |
| Nonmalignant hematologic disorders | 40 | (12.5) | 5 | (25) |
| Central nervous system tumor | 34 | (10.6) | 1 | (5) |
| Sarcoma | 31 | (9.7) | 3 | (15) |
| Thyroid cancer | 27 | (8.4) | 1 | (5) |
| Wilms tumor | 17 | (5.3) | 1 | (5) |
| Other solid tumor | 9 | (2.8) | 1 | (5) |
| Retinoblastoma | 7 | (2.2) | 1 | (5) |
| Myelodysplastic syndrome | 3 | (0.9) | 1 | (5) |
| History of hematopoietic cell transplantation | ||||
| Total | 99 | (30.9) | 7 | (35) |
| Allogeneic | 68 | (21.2) | 7 | (35) |
| Autologous | 31 | (9.7) | 0 | (0) |
| Blood type, No. (%) | ||||
| O positive/O negative | 114/8 | (38.1) | 6 / 0 | (30) |
| A positive/A negative | 84/8 | (28.8) | 7 / 0 | (35) |
| B positive/B negative | 40/2 | (13.1) | 3 / 0 | (15) |
| AB positive/AB negative | 17/2 | (5.9) | 1 / 0 | (5) |
| Records not available | 45 | (14.1) | 3 | (15) |
| Age at study, years | ||||
| Median (range) | 15.1 (2.7‐25.2) | 17 (9.1‐20.8) | ||
| 1‐10 | 57 | (17.8) | 1 | (5) |
| 10‐20 | 229 | (71.3) | 18 | (90) |
| 20‐26 | 35 | (10.9) | 1 | (5) |
| Years from diagnosis | ||||
| Median (range) | 8.9 (1.2‐20.4) | 10.7 (3.3‐19.6) | ||
| Years from end of treatment | ||||
| Median (range) | 6.9 (1.0‐18.6) | 6.2 (1.7‐14.1) | ||
| 1‐5 | 113 | (35.2) | 9 | (45) |
| 5‐10 | 127 | (39.6) | 7 | (35) |
| Over 10 | 81 | (25.2) | 4 | (20) |
| Location of primary residence, No (%) | ||||
| Bronx | 12 | (3.7) | 4 | (20) |
| Kings County, Brooklyn | 47 | (14.6) | 6 | (30) |
| Manhattan | 29 | (9.0) | 1 | (5) |
| Nassau County | 22 | (6.9) | 0 | (0) |
| New Jersey | 70 | (21.8) | 1 | (5) |
| Other New York county | 11 | (3.4) | 0 | (0) |
| Other state | 47 | (14.6) | 1 | (5) |
| Queens | 19 | (5.9) | 3 | (15) |
| Rockland County | 9 | (2.8) | 2 | (10) |
| Staten Island | 12 | (3.7) | 0 | (0) |
| Suffolk County | 25 | (7.8) | 1 | (5) |
| Westchester | 18 | (5.6) | 1 | (5) |
| Type of visit, No. (%) | ||||
| In‐person | 227 | (70.7) | 17 | (85) |
| Telehealth | 94 | (29.3) | 3 | (15) |
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.